Scoring treatment response in patients with relapsing multiple sclerosis
Maria Pia Sormani(University of Genoa), Nicola De Stefano(University of Siena), Bettina Stubinski(Merck Serono S.A. (Switzerland)), Alessio Signori(University of Genoa), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), ML Stromillo(University of Siena), Mar Tintoré(Vall d'Hebron Hospital Universitari), Peter Cornelisse(Merck Serono S.A. (Switzerland)), Jordi Río(Universitat Autònoma de Barcelona), D Li(University of British Columbia)
Cited by 258
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k